SINGAPORE -- Nasdaq-listed BioNTech, which is testing a COVID-19 vaccine candidate, said Monday it has raised $250 million from Singapore state-owned investment company Temasek and other accredited investors in a private placement.
DealStreetAsia
Singapore Temasek invests in COVID vaccine testing company
German BioNTech raises $250m from the sovereign wealth fund and others
Singapore state-owned investment company Temasek has targeted multiple biotechnology companies for investments. © Reuters
Read Next
Latest on DealStreetAsia
